Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Adenocarcinoma

Stomach Neoplasms

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Tubulin Modulators

Antimitotic Agents

Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.

Taxotere will be administrated by intravenous infusion once every 3 weeks.

Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.

Docetaxel for injection (Albumin-bound)

Taxotere, by intravenous infusion, every 3 weeks.

Taxotere

Ruihua Xu

This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

One hundred patients with locally advanced or metastatic gastric adenocarcinoma or gastric esophageal junction adenocarcinoma will be randomly assigned to the test group or the control group. All patients will receive Docetaxel for injection (Albumin-bound) or Taxotere for treatment until disease progression. Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

The duration is from the randomized time to disease progression or death due to any reason.

The primary endpoint is objective response rate,which equals CR+PR.

The primary endpoint is Disease Control rate,which equals CR+PR+SD.

The time from the first assessment of tumor as CR or PR to the first assessment as PD or death from any cause

OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer	NCT05705635	Gastric Adenoca... Adenocarcinoma ...	Docetaxel for i... Taxotere	18 Years - 75 Years	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer	NCT05705635	Gastric Adenoca... Adenocarcinoma ...	Docetaxel for i... Taxotere	18 Years - 75 Years	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Spots Global Cancer Trial Database for adenocarcinoma of gastroesophageal junction